Hormonal · Dosing reference

Abaloparatide dosage

Dosing as the FDA label states it, how long trials ran, and the arithmetic for working with vials.

FDA-approvedAHuman trial evidenceFDA label

Full research page Cycle-length evidence Compare Prefer Amiravo on Google

Regulatory status: FDA-approved
Human amounts: 80 micrograms once daily
Route studied: Subcutaneous injection
Frequency: Once daily
Half-life: Approximately 1 hour
Evidence grade: Grade A · Human trial evidence
Vial sizes on the market: Not recorded
Other forms seen: —

What Abaloparatide is

Abaloparatide is a synthetic 34-amino-acid analog of parathyroid hormone-related peptide, FDA-approved in 2017 as Tymlos for osteoporosis at high fracture risk in postmenopausal women and, to increase bone density, in men.

Abaloparatide acts as an agonist at the PTH1 receptor (PTH1R), activating cAMP signaling in target cells ^1. Bone effects Once-daily administration stimulates new bone formation on trabecular and cortical surfaces through osteoblastic activity ^1. In rats and monkeys it increased BMD and bone mineral content, correlating with bone strength ^1. In postmenopausal women, the formation marker sPINP peaked at 93% above… How it works →

Key evidence

Miller et al., JAMA (ACTIVE, NCT01343004) · 2016 · Humans (2,463 postmenopausal women with osteoporosis)
New vertebral fractures lower than placebo; nonvertebral fracture event rate lower; hypercalcemia 3.4% versus 6.4% with teriparatide ^2. ²
Tymlos prescribing information, Section 14.1 (Studies 003 and 005) · 2026 · Humans (postmenopausal women; mITT 690 vs 711)
New vertebral fractures 0.6% versus 4.2% at 18 months (RRR 86%) and 0.6% versus 4.4% at 25 months after alendronate (RRR 87%); lumbar spine BMD +9.2% versus +0.5% ^1. ¹
Czerwinski et al., J Bone Miner Res (ATOM, NCT03512262) · 2022 · Humans (228 men aged 40-85 with osteoporosis)
Lumbar spine BMD +8.48% versus +1.17%; total hip +2.14% versus +0.01%; femoral neck +2.98% versus +0.15% ^3. ³

All studies on the research page

Schedules by time period

Label regimens and laid out week by week. Each bar is what the label states or what investigators gave participants; none is a recommendation.

FDA label

Tymlos (FDA label): dosing ¹

Postmenopausal women and men with osteoporosis at high fracture risk · 104 weeks

Abaloparatide

SC · once daily

Week-by-week table

Period	Amount
Weeks 0–onward	80 mcg (maintenance)

Single fixed dosage; no escalation.

Lifetime use beyond 2 years is not recommended.

Dosing as stated on the FDA label

The recommended dosage is 80 micrograms subcutaneously once daily, with supplemental calcium and vitamin D if dietary intake is inadequate ^1.
Safety and efficacy have not been evaluated beyond 2 years; use for more than 2 years during a patient's lifetime is not recommended ^1.
Do not administer intravenously or intramuscularly; give the first several doses where the patient can sit or lie down. Other administration instructions are in the label and are not reproduced here ^1.

How long did human studies run?

No human study durations are recorded for Abaloparatide.

Cycle-length evidence for Abaloparatide

Side effects reported in studies

Hypercalciuria
11% versus 9% placebo · Postmenopausal women, 18-month trial (n=822 vs 820) ¹
Dizziness
10% versus 6% · Same trial ¹
Nausea
8% versus 3% · Same trial ¹
Headache
8% versus 6% · Same trial ¹
Palpitations
5% versus 0.4% · Same trial ¹
Injection site redness
58% versus 28% · Daily assessment during the first month ¹
Hypercalcemia (corrected calcium 10.7 mg/dL or higher at 4 hours)
3% versus 0.1% · Postmenopausal women trial ¹
Elevated serum uric acid
25% versus 6% with at least one value above normal · Patients with normal baseline uric acid ¹

Full adverse-event data

Supplies and handling

Lyophilized vial
Sealed vial with the freeze-dried cake. Check the label, lot and the certificate of analysis before opening.
Sterile diluent
The diluent named on the product documentation. Bacteriostatic water contains benzyl alcohol; sterile water does not.
Graduated syringes
Sized to the volume being measured. U-100 insulin syringes are graduated in units where 100 units = 1 mL.
Alcohol prep pads
For wiping vial stoppers before each puncture.
Nitrile gloves
Clean gloves for aseptic handling.
Sharps container
Puncture-resistant container for used needles.

Step-by-step reconstitution guide Storage and transport accessories

Storage

The label directs refrigerated storage (2-8°C) before first use; after first use, up to 30 days at 20-25°C; do not freeze or expose to heat ^1.

Lyophilized (unmixed) vials: typically stored cold and dry, away from light, as the documentation directs. Many are stable longer frozen.
Reconstituted vials: typically refrigerated (about 2–8 °C), protected from light and not frozen.
Bacteriostatic water contains benzyl alcohol, which inhibits bacterial growth in multi-use vials; sterile water has no preservative.

Handling mistakes and troubleshooting

Added the wrong volume of diluent: The concentration changes, not the amount of compound in the vial. Recalculate with the volume actually added and relabel the vial.
Shook the vial and it foamed: Let it settle in the refrigerator. Foam is a sign of agitation; some peptides aggregate when shaken. Note it on the label.
The solution is cloudy or has particles: Do not use it. Cloudiness can indicate incomplete dissolution, contamination or degradation. Record the lot and contact the supplier with the certificate of analysis.
The powder cake looks melted or shrunken before reconstitution: This can indicate the vial was exposed to heat or moisture. Record the lot and condition on arrival.
Liquid sprayed back when the needle was removed: Pressure built up in the vial. Withdraw a small volume of air while adding diluent to keep pressure neutral.

Regulatory status

Status: FDA-approved (initial U.S. approval 2017) as Tymlos, NDA 208743, listed with prescription marketing status as of 2026-10-24 ^1,4.
United States (FDA): FDA-approved (initial U.S. approval 2017) as Tymlos, NDA 208743, with prescription marketing status per Drugs@FDA as of 2026-10-24 ^1,4.
Sport (WADA): Parathyroid hormone and PTHrP analogs, including abaloparatide, were not mentioned on the WADA 2026 Prohibited List page reviewed ^5.

Status varies by country and changes over time. How we describe regulatory status.

Abaloparatide compared with related compounds

Compound	Status	Evidence	Human amounts	Half-life
Abaloparatide	FDA-approved	A	FDA label	Approximately 1 hour
PEA	Not approved — research use only	A	None established	—
Vesugen	Not approved — research use only	C	None established	—
Kisspeptin-54	Not approved — research use only	B	None established	About 28 minutes (intravenous, healthy m
Apelin-13	Not approved — research use only	B	None established	Not located as a numeric value in the so
hCG (human chorionic gonadotropin)	FDA-approved	A	FDA label	About 29 hours (recombinant hCG, subcuta

Frequently asked questions

What doses of Abaloparatide have been studied in humans?

Abaloparatide is FDA-approved, so the label states the dosing for the approved product. This page quotes it, with citations. It does not apply to research-grade material.

Is there an established Abaloparatide cycle length?

No. We found no human studies that report treatment duration for Abaloparatide.

How much bacteriostatic water should be added to a Abaloparatide vial?

There is no compound-specific volume. The diluent volume only sets the concentration: concentration = mass in the vial ÷ volume added (for example, 10 mg in 2 mL gives 5 mg/mL). The calculator on this page shows the arithmetic for any combination.

How many units is a given amount on an insulin syringe?

On a U-100 syringe, 100 units = 1 mL. Units for an amount = amount ÷ (concentration per unit). The calculator converts any amount you enter at the concentration you choose; a unit is a volume mark, not an amount of compound.

What is the half-life of Abaloparatide?

Approximately 1 hour

Is Abaloparatide FDA-approved?

FDA-approved. FDA-approved (initial U.S. approval 2017) as Tymlos, NDA 208743, listed with prescription marketing status as of 2026-10-24 ^1,4.

References

TYMLOS (abaloparatide) injection, for subcutaneous use, prescribing information (DailyMed, effective 08/2026) FDA label (DailyMed). 2026
Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial (ACTIVE) JAMA. 2016
The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial (ATOM) J Bone Miner Res. 2022
Drugs@FDA (openFDA) application record NDA 208743, TYMLOS U.S. FDA. 2026
World Anti-Doping Agency Prohibited List 2026 (online version) WADA. 2026
PubChem compound record for abaloparatide PubChem. 2026

Last reviewed October 24, 2026 by the Amiravo editorial team. Editorial policy · Report an error